- Daewoong Bio has launched its Bio-Center in Hyangnam, South Korea, offering fully integrated CMO services.
- The facility provides drug substance and drug product manufacturing, including multiple dosage formats and regulatory support.
Daewoong Bio has launched its new Bio-Center in Hyangnam, South Korea, designed to provide end-to-end contract manufacturing services for microbial-based biopharmaceuticals.
The facility integrates both drug substance (DS) and drug product (DP) manufacturing. DS manufacturing includes fermentation at up to 900 litres working volume, while DP manufacturing supports formats such as liquid vials, lyophilised vials, cartridges, sprays, and pre-filled syringes at a rate of up to 12,000 units per hour.
In addition to manufacturing, the Bio-Center offers technology transfer, process optimisation, PPQ/CPV, regulatory support for IND, BLA and PMA filings, and cost optimisation services. The site has been designed for compliance with cGMP standards, with a focus on speed, flexibility, and scalability.
